CALIFORNIA | LOCAL
August 5, 2011 | By Thomas H. Maugh II, Los Angeles Times
Physicist John H. Marburger III, who served as President George W. Bush's science advisor at a time when most researchers considered science to be under attack by the government, died July 28 at his home in Port Jefferson, N.Y. He was 70 and had non-Hodgkins lymphoma. He also served as dean of USC's College of Letters, Arts and Sciences, as president of State University of New York at Stony Brook and as head of Brookhaven National Laboratory on Long Island. "Jack Marburger was a superb advocate for science, a visionary leader, and a highly skilled administrator who successfully led three vital institutions," said Dr. Samuel L. Stanley Jr., the current president of Stony Brook.
BUSINESS
June 16, 2011 | By Nathaniel Popper, Los Angeles Times
A controversial and often risky corner of the municipal bond market should be subject to more oversight, according to a new report by an advisory committee appointed by the Internal Revenue Service. The report released Wednesday said the IRS has provided insufficient rules and guidance for issuing so-called conduit bonds, an increasingly popular way for private entities to access low-cost, tax-free municipal bond financing. State and local governments are paid fees to issue these bonds on behalf of companies or nonprofits for projects to boost economic development.
FOOD
March 11, 2011 | By David Karp
It is not very often that meetings of the Certified Farmers Market Advisory Committee are the stuff of high drama. But such was the case Thursday at a meeting in Sacramento at which the committee voted to recommend a substantial increase in fees paid by market vendors, in order to fund a more effective market enforcement program. The vote is the latest step in a process started last November in the wake of news reports of rampant cheating at Southern California certified farmers markets.
NEWS
November 18, 2010 | By Thomas H. Maugh II, Los Angeles Times
A Food and Drug Administration advisory committee Wednesday recommended that the agency extend approval of the human papillomavirus (HPV) vaccine Gardasil for protection against anal cancer in males and females ages 9 through 26. The agency is not required to follow the recommendations of its advisory committees, but it generally does so. Anal cancer is relatively uncommon, striking about 5,000 Americans each year. About 90% of cases are thought to be caused by HPV. Gardasil protects against four of the most common strains of HPV. It is already licensed for protection against cervical cancer in women and against genital warts in both sexes ages 9 to 26. The new indication was based primarily on a clinical trial conducted among 4,065 men, 602 of them gay. Patients were randomly assigned to receive either three doses of the vaccine or a placebo.
NEWS
October 27, 2010 | By Thomas H. Maugh II, Los Angeles Times
A Centers for Disease Control and Prevention advisory committee on Wednesday recommended that adolescents receive a booster shot of the meningitis vaccine at age 16 because the effects of the vaccine fade more quickly than had been anticipated. [ Updated Wednesday, 11:15 a.m.: The original version of this story incorrectly said that it was an FDA advisory committee that made the recommendation.] Researchers had originally thought that the benefits of the vaccine persisted for at least 10 years, but new evidence presented to the committee Wednesday suggests that its benefits begin to wane after five years.
NATIONAL
July 15, 2010 | By Andrew Zajac and Thomas H. Maugh II, Los Angeles Times
Faced with conflicting and less-than-conclusive scientific evidence, a Food and Drug Administration advisory panel recommended Wednesday that the controversial diabetes drug Avandia remain on the market — but with tighter supervision and increased warnings about the danger of heart attacks. Advisory recommendations are not binding and the FDA is expected to take at least several weeks to consider its response, but the panel's expression of increased concern is likely to further reduce doctors' reliance on what was once the drug of choice for treating Type II diabetes.